Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Clinical Trial Grant
Administered By
Pediatrics, Allergy and Immunology
Awarded By
Takeda Development Center Americas, Inc
Start Date
February 20, 2024
End Date
February 1, 2026
Administered By
Pediatrics, Allergy and Immunology
Awarded By
Takeda Development Center Americas, Inc
Start Date
February 20, 2024
End Date
February 1, 2026